The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You'd have to think they've got the funding lined up...pay decrease of 25% for a few months will be more than compensated for by even a modest rise on 1,000,000 shares. The pay decrease gives them a great excuse for more options...without appearing greedy
Nobody talking about trial centres outside UK and US...is that because people dont expect them to materialize...or because people dont want to draw attention to the fact it may well mean no additional UK trial centres.
Apologies if this has already been shared but the investival vid is up on YouTube.
https://youtu.be/xoJ--zgbl9s
Not much new info but
1. They are looking at other countries to add trial centres for scib1 trial, not just US and UK.
2. Scib2 starting next year
3. A bit more in depth science on avidimab.
CH on 19th August: "Given that we had patients here in the UK awaiting enrolment in to the study..." so are we to assume then that none of these patients awaiting enrolment were suitable for treatment? Surely it would be unethical to keep patients from enrolling in other studies on the basis that they may or may not even be suitable for our study? Surely if they are awaiting enrolment, they should be screened for suitability first...? So either we didn't have anybody awaiting enrolment, or they chose to go with different trials...